Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study-Reference-Cited by-同舟云学术

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Published:2022-11 Issue: Volume:175 Page:204-213
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Fulgenzi Claudia Angela Maria,Cheon Jaekyung,D'Alessio Antonio,Nishida Naoshi,Ang Celina,Marron Thomas U.,Wu Linda,Saeed Anwaar^ORCID,Wietharn Brooke^ORCID,Cammarota Antonella^ORCID,Pressiani Tiziana,Personeni Nicola^ORCID,Pinter Matthias,Scheiner Bernhard,Balcar Lorenz^ORCID,Napolitano Andrea,Huang Yi-Hsiang,Phen Samuel^ORCID,Naqash Abdul Rafeh,Vivaldi Caterina,Salani Francesca,Masi Gianluca^ORCID,Bettinger Dominik,Vogel Arndt^ORCID,Schönlein Martin,von Felden Johann,Schulze Kornelius,Wege Henning,Galle Peter R.^ORCID,Kudo Masatoshi,Rimassa Lorenza^ORCID,Singal Amit G.,Sharma Rohini,Cortellini Alessio^ORCID,Gaillard Vincent E.^ORCID,Chon Hong Jae,Pinato David James^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020

2. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma;Cheng;J Hepatol,2022

3. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial;Galle;Lancet Oncol,2021

4. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update;Reig;J Hepatol,2022

5. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice;Hayakawa;Investig New Drugs,2022

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cucurbitacin I exerts its anticancer effects by inducing cell cycle arrest via the KAT2a-ube2C/E2F1 pathway and inhibiting HepG2-induced macrophage M2 polarization;Biochemical and Biophysical Research Communications;2024-12

2. Hepatocellular carcinoma imaging: Exploring traditional techniques and emerging innovations for early intervention;Medicine in Novel Technology and Devices;2024-12

3. Real-World Outcomes of Atezolizumab with Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications;Cancers;2024-08-19

4. Outcomes and safety of atezolizumab plus bevacizumab in the treatment of hepatocellular carcinoma: treatment prognosis and comparison with tyrosine kinase inhibitors in a French multicenter matched real-life study;European Journal of Gastroenterology & Hepatology;2024-07-26

5. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment;Hepatology;2024-07-19